TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05804929

Intervention type: OTHER
Intervention: Observation without intervention
Description: Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.

Intervention type: OTHER
Intervention: Observation without intervention
Description: Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.
Study: NCT05125003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FITBI
Description: parents learn to identify high probability cues in the environment that can elicit RRBI symptoms and teach their child to inhibit repetitive behaviors and instead replace them with alternative and flexible play behaviors; and (b) teach parents how to embed this FITBI approach into their child's everyday routines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental Education
Description: Sessions will cover relevant information on young children with ASD, including understanding the ASD diagnosis, developmental changes in ASD, educational planning, advocacy, and treatment options.
Study: NCT05626933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccinator myomucosal flap with Furlow palatoplasty
Description: Anatomical restoration concept using Buccinator myomucosal flap with Furlow palatoplasty is an effective technique for lengthening the palate and improving speech outcomes
Study: NCT06218810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab + bevacizumab + FOLFOX
Description: Cadonilimab + bevacizumab + FOLFOX
Study: NCT06487299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Lactate
Description: The injection solution was 3 ferrous lactate (10ml:0.1g iron) mixed with 20ml saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: The injection was 3 shots of ferrous lactate (5ml:100mg iron) mixed with 35ml saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: The same volume and color as Iron sucrose.
Study: NCT04630925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isCGM
Description: As previously described
Study: NCT05771714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareSuperb COVID-19 Antigen Home Test Kit
Description: At home COVID-19 antigen test kit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareSuperb COVID-19 Antigen Home Test Kit
Description: At home COVID-19 antigen test kit
Study: NCT06259318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kanasina Gulabi
Description: Kanasina Gulabi is a theory-driven, educational-behavioral intervention designed to improve the quality of life and diabetes management among young adults living with type 2 diabetes in Mysore district, South India. In this intervention, young adults with type 2 diabetes were matched to non-specialist peer navigators -- trained young adult peers who were also managing type 2 diabetes -- and developed action plans to improve their physical and mental health outcomes. Intervention components included group education, mindfulness activities, self care activity tracking, and phone follow-ups to address knowledge gaps and misinformation about type 2 diabetes, build self-efficacy for type 2 diabetes-related self care activities, and provide emotional support for diabetes management.
Study: NCT06393842

Intervention type: DEVICE
Intervention: Cardiopulmonary Management Wearable Device
Description: Fluid status and congestion can be determined by the CPM wearable device and correlates with non-invasive measures and biochemical markers of congestion and changes in congestion.

Intervention type: DEVICE
Intervention: Cardiopulmonary Management Wearable Device
Description: Fluid status and congestion can be determined by the CPM wearable device and correlates with non-invasive measures and biochemical markers of congestion and changes in congestion.
Study: NCT05850767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Participants will stay fully awake for 24 hours
Study: NCT05658718

Intervention type: PROCEDURE
Intervention: refractive surgery
Description: refractive surgery

Intervention type: PROCEDURE
Intervention: refractive surgery
Description: refractive surgery
Study: NCT05456529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
Study: NCT04176666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NettOpp
Description: NettOpp is a mobile application for adolescents aged 11-16 years who have been exposed to cyberbullying or cyberaggression.
Study: NCT05660603

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: patients will receive standard general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSP
Description: patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CP
Description: patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: ultrasound
Study: NCT06323070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat cookies
Description: To determine the effects of low-fat cookie consumption on physiological indicators of wellness regarding sexual, skin, and gut health
Study: NCT05566743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: maintenance capecitabine after 4 months of FOLFRINOX

Intervention type: OTHER
Group type: OTHER
Intervention: follow up
Description: follow up after 4 months of FOLFRINOX
Study: NCT06323070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon
Description: To determine the effects of watermelon consumption on physiological indicators of wellness regarding sexual, skin, and gut health
Study: NCT05120700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synovial Tissue and Fat Pad Stromal Vascular Fraction
Description: Treatment of cartilage injury with a tissue engineering construct. It will be composed of stromal vascular fraction collected from the synovial membrane and infrapatellar fat of the injured knee, submitted to enzymatic processing in a single surgical time, associated with a collagen scaffold
Study: NCT04982991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIPK1 inhibitor
Description: Capsule Oral
Study: NCT05988736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MaCintosh Laryngoscope (DL)
Description: A conventional Laryngoscope. It is battery powered, with a detachable MaCintosh blade that contains a light source.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath Laryngoscope (VL)
Description: A video Laryngoscope that has a high-resolution video camera, and a light source at the cone end of the blade allowing for direct and indirect viewing of the glottis
Study: NCT05357833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol infusion
Description: Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Brain and Cervical Spine
Description: 3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
Study: NCT05385211

Intervention type: OTHER
Intervention: Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency
Description: Blood samplings; Glucose monitoring; CFTR variants
Study: NCT05027919

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: 30mg subcutaneous injections of morphine 4 times daily on days 1 through 5.

Intervention type: DRUG
Group type: OTHER
Intervention: Naloxone + lofexidine pretreatment
Description: 0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)

Intervention type: DRUG
Group type: OTHER
Intervention: Naloxone + placebo pretreatment
Description: 0.4mg naloxone injection during the Naloxone challenge

Intervention type: DRUG
Group type: OTHER
Intervention: Lofexidine
Description: Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
Study: NCT05733364

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsules with B vitamins & taurine
Description: Administered orally in a span of 28 days between mealtimes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose placebo
Description: Administered orally in a span of 28 days between mealtimes
Study: NCT05913479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucogyne Gel
Description: At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)
Study: NCT05450835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OGT group
Description: In OGT group,the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Meanwhile, the OGT was sleeved on anvil fork extracorporeally and the linear stapler was put into abdomen through trocar on the right side and then cartridge fork was inserted through jejunum opening towards the oral side of the lumen. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Overlap group
Description: In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al.
Study: NCT06528899

Intervention type: BEHAVIORAL
Intervention: Physical Therapy
Description: Assessment and/or treatment by physitoherapist during the visit
Study: NCT05579730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo
Description: Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo
Description: Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo
Description: Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo
Description: Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate ophthalmic solution 0.035%
Description: Ketotifen fumarate ophthalmic solution 0.035%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate ophthalmic solution 0.035%
Description: Ketotifen fumarate ophthalmic solution 0.035%
Study: NCT05066763

Intervention type: OTHER
Intervention: Non-interventional
Description: non-interventional
Study: NCT05579730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate ophthalmic solution 0.035%
Description: Ketotifen fumarate ophthalmic solution 0.035%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate ophthalmic solution 0.035%
Description: Ketotifen fumarate ophthalmic solution 0.035%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution 0.025%
Description: Brimonidine tartrate ophthalmic solution 0.025%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution 0.025%
Description: Brimonidine tartrate ophthalmic solution 0.025%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution 0.025%
Description: Brimonidine tartrate ophthalmic solution 0.025%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution 0.025%
Description: Brimonidine tartrate ophthalmic solution 0.025%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ophthalmic solution
Description: Vehicle ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ophthalmic solution
Description: Vehicle ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ophthalmic solution
Description: Vehicle ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ophthalmic solution
Description: Vehicle ophthalmic solution
Study: NCT05404971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint integrity exercises
Description: patients with three strokes followed by 3 sec rest period. Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
Study: NCT05910515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing
Description: Structured debriefing in non-technical skills. (This is an educational study)
Study: NCT06320600

Intervention type: OTHER
Intervention: no intervention
Description: It's an observational study, no intervention included

Intervention type: OTHER
Intervention: no intervention
Description: It's an observational study, no intervention included
Study: NCT06375083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The computerized Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) course is comprised of 12 online sessions and is augmented by use of a companion workbook. The computerized Cognitive Behavioral Therapy for Depression (cCBT-D) course is comprised of 12 online sessions.
Study: NCT05880251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant Conditioning with Peripheral Stimulation
Description: This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation. Non-painful peripheral stimulation will be applied to elicit a response.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group with Peripheral Stimulation Only
Description: This is a control intervention in which the non-painful peripheral stimulation will be applied, same as the operant conditioning group, but no training feedback will be provided.
Study: NCT06174870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inhale against 60% of Maximal inspiratory pressure 30breaths/day 5days/week for 6 weeks
Study: NCT05335733

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoral examination, saliva, dental plaque and serum collection.
Description: Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoral examination, saliva, dental plaque and serum collection.
Description: Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit.
Study: NCT05589844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo standard of care allogeneic hematopoietic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine
Description: Given intradermally
Study: NCT06114394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UPV/EHU technique (Aguirre-Zorzano et al 2017)
Description: The UPV/EHU technique (Aguirre-Zorzano et al., 2017) begins with the elevation of the full thickness flap (FTF) in the palate and an intrasulcular incision performed with a number 12 blade, preserving the papillae in the interproximal spaces. Then, the FTF is dissected with a 15c blade, holding the flap with tissue forceps, leaving the epithelium and a thin layer of the connective tissue in the flap, so that the underlying connective tissue can be harvested. After that the flap is sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single incision technique (Huerzeler & Weng 1999)
Description: The CTG is harvested with the single incsion technique described by Huerzeler \& Weng in 1999.
Study: NCT04791033

Intervention type: PROCEDURE
Intervention: Hysterectomy
Description: Elective procedure with hysterectomy due to benign gynecological condition

Intervention type: PROCEDURE
Intervention: Hysterectomy
Description: Elective procedure with hysterectomy due to benign gynecological condition
Study: NCT05833971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab+chemotherapy
Description: cadonilimab plus cisplatin and Nab-PTX, Q3W
Study: NCT05355428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: offering of breast milk feed 3 hours prior to p lanned surgery start
Description: parents will be asked to offer a breast milk feed (from breast or expressed in bottle) at a given time 3 hours prior to planned induction time
Study: NCT04297826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harvest for Health
Description: Please see previous description
Study: NCT04856956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic decision support software
Description: Comparing use of decision support group (intervention group) to use only of common literature (control group) among pediatric trainees diagnosing patients with possible rheumatologic disorder
Study: NCT05249985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES
Description: Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will consume a daily protein supplement
Study: NCT05713578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apantamide+docetaxel+ADT
Description: Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apantamide+ADT treatment
Description: apantamide+ADT treatment
Study: NCT06189170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP405
Description: Experimental drug
Study: NCT05335291

Intervention type: OTHER
Intervention: Questionnaire study
Description: The Turkish validity and reliability of the questionnaire will be examined.